Diagnosis and management of MELAS

Department of Neurology, Institute of Psychiatry, King's College London, UK.
Expert Review of Molecular Diagnostics (Impact Factor: 3.52). 09/2004; 4(5):631-44. DOI: 10.1586/14737159.4.5.631
Source: PubMed


Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) is the most common maternally inherited mitochondrial disease. An A-->G mutation in the transfer RNA(Leu(UUR)) gene at position 3243 of the mitochondrial DNA accounts for most MELAS cases. The transient nature of the stroke-like episodes is reflected in abnormalities on neuroimaging. The cardinal laboratory abnormalities include elevated serum lactate during the acute episodes and respiratory enzyme defects in skeletal muscle. Muscle biopsy also helps confirm the diagnosis by identifying abnormal proliferation of mitochondria. Although current treatment options for MELAS are largely supportive, several therapeutic approaches have been attempted with limited success. Genetic counseling is an important component of patient management in MELAS. Newer reproductive technologies hold promise for reducing the recurrence of MELAS in subsequent generations. Advances in research into gene therapy offer hope of treatment for the future.

21 Reads
  • Source
    • "The present report regards an adult patient presenting all the clinical criteria for MELAS syndrome (stroke-like episodes, with onset before age 40; encephalopathy with seizures and cognitive impairment; mitochondrial myopathy with lactic acidosis, in the context of normal early psychomotor development and recurrent headache), as well as the most frequent complications, namely diabetes mellitus (initially defined as type 2 diabetes, but at present more often defined as mitochondrial diabetes) and sensorineural hearing loss [1]. Molecular genetic testing identified the most common mutation found in MELAS patients, MTTL1 (MIM ID *590050), encoding mitochondrial tRNA leucine 1(3243A > G transition) [1,20,21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: MELAS syndrome (MIM ID#540000), an acronym for Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-like episodes, is a genetically heterogeneous mitochondrial disorder with protean manifestations and occasional kidney involvement. Interest in the latter is rising due to the identification of cases with predominant kidney involvement and to the hypothesis of a link between mitochondrial DNA and kidney neoplasia. We report the case of a 41-year-old male with full blown MELAS syndrome, with lactic acidosis and neurological impairment, affected by the "classic" 3243A > G mutation of mitochondrial DNA, with kidney cancer. After unilateral nephrectomy, he rapidly developed severe kidney functional impairment, with nephrotic proteinuria. Analysis of the kidney tissue at a distance from the two tumor lesions, sampled at the time of nephrectomy was performed in the context of normal blood pressure, recent onset of diabetes and before the appearance of proteinuria. The morphological examination revealed a widespread interstitial fibrosis with dense inflammatory infiltrate and tubular atrophy, mostly with thyroidization pattern. Vascular lesions were prominent: large vessels displayed marked intimal fibrosis and arterioles had hyaline deposits typical of hyaline arteriolosclerosis. These severe vascular lesions explained the different glomerular alterations including ischemic and obsolescent glomeruli, as is commonly observed in the so-called "benign" arteriolonephrosclerosis. Some rare glomeruli showed focal segmental glomerulosclerosis; as the patient subsequently developed nephrotic syndrome, these lesions suggest that silent ischemic changes may result in the development of focal segmental glomerulosclerosis secondary to nephron loss. Nephron loss may trigger glomerular sclerosis, at least in some cases of MELAS-related nephropathy. Thus the incidence of kidney disease in the "survivors" of MELAS syndrome may increase as the support therapy of these patients improves.
    BMC Nephrology 02/2012; 13(1):9. DOI:10.1186/1471-2369-13-9 · 1.69 Impact Factor
  • Source
    • "mmol/L), CSF lactate of 4.6 mmol/L (normal: 1.1– 2.8 mmol/L) and CSF pyruvate of 3.5 mmol/L (Normal: 0.5–1.7 mmol/L). Genetic testing confirmed the presence of the A-to-G point mutation at the 3243 position in the mitochondrial DNA, which is diagnostic for MELAS [1]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a rare but important cause of stroke-like symptoms which can often be missed Thambisetty and Newman 2004. We describe a case of a young male presenting with stroke-like episodes, later diagnosed with MELAS in an attempt to improve the understanding about diagnosing MELAS in the appropriate clinical context.
    Stroke Research and Treatment 07/2011; 2011:140630. DOI:10.4061/2011/140630
  • Source
    • "Stroke-like events may be reversible or permanent both from clinical and radiological points of view. These lesions may be small or large, single or multiple, usually asymmetric and their distribution does not correspond to vascular supply areas (Pavlakis et al. 1984; Hirano et al. 1992; Thambisetty and Newman 2004). In the acute stage the lesions are swollen. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Brain MR imaging techniques are important ancillary tests in the diagnosis of a suspected mitochondrial encephalopathy since they provide details on brain structural and metabolic abnormalities. This is particularly true in children where non-specific neurologic symptoms are common, biochemical findings can be marginal and genetic defects may be not discovered. MR imaging modalities include conventional, or structural, imaging (MRI) and functional, or ultrastructural, imaging (spectroscopy, MRS; diffusion, DWI-ADC; perfusion, DSCI--ASL). Among them MRI and MRS are the main tools for diagnosis and work up of MD, and this review will focus mainly on them. The MRI findings of MD are very heterogeneous, as they depend on the metabolic brain defects, age of the patient, stage and severity of the disease. No correlation has been found between genetic defects and neuroimaging picture; however, some relationships between MR findings and clinical phenotypes may be identified. Different combinations of MRI signal abnormalities are often encountered but the most common findings may be summarized into three main MR patterns: (i) non-specific; (ii) specific; (iii) leukodystrophic-like. Regarding the functional MR techniques, only proton MRS plays an important role in demonstrating an oxidative metabolism impairment in the brain since it can show the accumulation of lactate, present as a doublet peak at 1.33 ppm. Assessment of lactate should be always performed on brain tissue and on the ventricular cerebral spinal fluid. As for MRI, metabolic MRS abnormalities can be of different types, and two distinct patterns can be recognized: non-specific and specific. The specific metabolic profiles, although not frequent to find, are highly pathognomonic of MD. The un-specific metabolic profiles add value to structural images in allowing to define the lesion load and to monitor the response to therapy trials.
    Bioscience Reports 07/2007; 27(1-3):69-85. DOI:10.1007/s10540-007-9046-z · 2.64 Impact Factor
Show more